NOTE: This article is based on research that utilizes the sources cited here as well as the collective experience of the Lab Tests Online Editorial Review Board. This article is periodically reviewed by the Editorial Board and may be updated as a result of the review. Any new sources cited will be added to the list and distinguished from the original sources used.

We have included the web address to online sources used in developing and reviewing this article for documentation purposes only. Links included on this Sources page are valid, working links at the time they are posted. Please be aware that the source owner may, from time to time, reorganize the source web site, which can result in broken links on our pages. If you wish to access a source and come across a broken link, you may still be able to access it by entering just the parent web address in your browser's address bar (eg, "www.nih.gov") and then by entering the source title in the site's search feature.

S2
Phend, C. (2005 September 27). Vancomycin Monitoring Uncommon for Pediatric Patients: Presented at ACCP [11 paragraphs]. Doctor’s Guide [On-line information]. Available FTP: http://www.pslgroup.com/dg/2533B6.htm

S3
Briceland, L. (2005 October 20). Vancomycin Trough Levels [3 paragraphs]. Medscape, Ask the Experts about Pharmacotherapy [On-line information]. Available FTP: http://www.medscape.com/viewarticle/514670

S4
Briceland, L. (2005 October 13). Vancomycin Duration of Treatment [5 paragraphs]. Medscape, Ask the Experts about Pharmacotherapy [On-line information]. Available FTP: http://www.medscape.com/viewarticle/514363

S5
(© 2003). Vancomycin (Vancocin ®), Serum, Peak [18 paragraphs]. Labcorp [On-line information]. Available FTP: http://www.labcorp.com/datasets/labcorp/html/chapter/mono/td024700.htm

S6
(1999 June 15). Vancomycin (Systemic) [32 paragraphs] MayoClinic.com [On-line information]. Available FTP: http://www.mayoclinic.com/health/drug-information/DR202590

S7
Darko, W. et. al. (2003 June 17). Mississippi Mud No More: Cost-Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent Nephrotoxicity [25 paragraphs]. Medscape from Pharmacotherapy 23(5):643-650. [On-line information]. Available FTP: http://www.medscape.com/viewarticle/455754

S8
Middlebrooks, M. (2003 September 22, Revised). Vancomycin Monitoring Protocol [18 paragraphs]. LSU Health Sciences Center – Shreveport Department of Pharmacy Services [On-line information]. Available online

S9
(2006 April, Updated). Laboratory Detection of Vancomycin-Intermediate/Resistant Staphylococcus aureus (VISA/VRSA) [21 paragraphs]. [On-line information]. Available FTP: http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_labFAQ.html

S10
Marraffa, J. et. al. (2003 October 14). Vancomycin-Induced Thrombocytopenia: A Case Proven With Rechallenge [25 paragraphs]. Medscape from Pharmacotherapy 23(9):1195-1198 [On-line information]. Available FTP: http://www.medscape.com/viewarticle/461407

S11
Fraser, T. et. al. (2005 October 11). Vancomycin and Home Health Care [26 paragraphs]. Medscape, from Emerg Infect Dis [On-line information]. Available FTP: http://www.medscape.com/viewarticle/513521

S12
(1999 June 15, Revised). Vancomycin (Systemic) [26 paragraphs]. MedlinePlus Drug Information [On-line information]. Available FTP: http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202590.html

S13
Keyserling, H. et. al. (2003). Vancomycin use in hospitalized pediatric patients [1 paragraph]. Medscape from Pediatrics 112(2):e104-11 [On-line information]. Available FTP: http://www.medscape.com/medline/abstract/12897315?queryText=vancomycin

S14
James, C. and Gurk-Turner, C. (2001 April). Recommendations for monitoring serum Vancomycin concentrations [10 paragraphs]. Baylor University Medial Center Proceedings 14:189-190 [On-line information]. Available FTP: http://www.baylorhealth.edu/proceedings/14_2/14_2_gurk-turner.html